1103 therapies in EGPA is not well established, some patients may benefit. Where possible, consultation with an otolaryngologist with expertise in treating AAV should be obtained to guide the use and choice of these agents. These interventions can continue to be beneficial even when symptoms have improved or resolved. Recommendation: For patients with EGPA who are receiving cyclophosphamide or rituximab, we conditionally recommend prescribing medications for prophylaxis to prevent P jirovecii